Bryan Johnson: the entrepreneur who turned his body into a business

Bryan Johnson made his fortune in payments, then spent it on his own biology. His longevity company Blueprint now sells the method, from supplements to a $1 million programme.

The product is the founder himself.

From payments to biology

Bryan Johnson built Braintree, the payments platform that absorbed Venmo, and sold it to PayPal for $800 million in 2013. He then founded the neurotechnology firm Kernel and OS Fund, which invests in frontier science. In 2021 came Project Blueprint, a data-driven regimen combining a strict vegan diet, more than 100 daily supplements, rigorous exercise and experimental therapies. The experiment costs him roughly $2 million a year. Johnson publishes his supplement stack, diet, exercise routine and test results for anyone to follow, and a 2025 Netflix documentary, Don't Die, carried the story to a global audience. Transparency became the marketing plan.

A $60 million bet on one man

In October 2025, Blueprint raised $60 million from investors including Kim Kardashian, Paris Hilton, Naval Ravikant and the Winklevoss twins. Gyre Renwick, previously president of Modern Health and an executive at Google Health and Lyft Healthcare, became CEO, while Johnson concentrates on vision and the Don't Die movement. The company sells food and supplements, from olive oil to a "longevity mix" powder, and plans a wider platform spanning diagnostics, nutrition, prescriptions, skincare and AI coaching. The turnaround came fast: in July 2025, Johnson had publicly considered giving up Blueprint altogether. In February 2026 he pushed the logic to its limit with Immortals, a programme priced at $1 million per year and limited to three participants. Buyers receive his exact protocol, a dedicated concierge team, continuous biological monitoring and round-the-clock guidance from BryanAI, an AI system modelled on Johnson. A $60,000 supported tier and a free digital tier should follow. For comparison, Biograph's premium membership costs $15,000 per year and Fountain Life's top programme $21,500. The product is the founder himself.

When the proof falls ill

On June 30, 2026, Johnson announced a diagnosis of autoimmune gastritis, an incurable disease he discovered only in May. Doctors had noticed persistently low iron levels, and an endoscopy with biopsies confirmed an early-stage form. Johnson turned the news into an argument for his method. He wrote that without five years of careful health management, his situation could be far more serious, and that in the age of AI and custom-built cells, no condition should be presumed incurable. Critics read the episode differently. Immortals remains a privately funded experiment with no control group, no peer review and no regulatory oversight. A Northwestern data scientist observed that the most measured human alive still carried the condition undetected for years. For a company whose founder serves as the evidence, a diagnosis counts as a business risk as much as a medical one. Blueprint's backers now hold a stake in a brand and in a patient.

Story generated by AI and proofread by Marc Auxenfants